CervoMed

Update in progress

CRVO (NasdaqCM)

CervoMed Inc. is a clinical‑stage biotechnology company focused on developing and commercializing treatments for age‑related neurologic disorders. It is advancing neflamapimod, an oral small molecule that crosses the blood–brain barrier and inhibits the p38α enzyme, with the aim of reversing synaptic dysfunction and supporting neuron health. The program targets dementia with Lewy bodies, nonfluent variant primary progressive aphasia, and ALS. Founded in 2010, it is based in Boston.